JP7782035B2 - Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール - Google Patents

Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール

Info

Publication number
JP7782035B2
JP7782035B2 JP2024526576A JP2024526576A JP7782035B2 JP 7782035 B2 JP7782035 B2 JP 7782035B2 JP 2024526576 A JP2024526576 A JP 2024526576A JP 2024526576 A JP2024526576 A JP 2024526576A JP 7782035 B2 JP7782035 B2 JP 7782035B2
Authority
JP
Japan
Prior art keywords
optionally substituted
int
nitrogen
sulfur
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2024526576A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540292A5 (https=
JP2024540292A (ja
Inventor
クレイグ イー． マッセ，
ジェレミー アール． グリーンウッド，
ジアイー シュー，
サヤン モンダル，
ファニ ガナコタ，
Original Assignee
エイジャックス セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイジャックス セラピューティクス， インコーポレイテッド filed Critical エイジャックス セラピューティクス， インコーポレイテッド
Publication of JP2024540292A publication Critical patent/JP2024540292A/ja
Publication of JP2024540292A5 publication Critical patent/JP2024540292A5/ja
Priority to JP2025153429A priority Critical patent/JP2025178324A/ja
Application granted granted Critical
Publication of JP7782035B2 publication Critical patent/JP7782035B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2024526576A 2021-11-09 2022-11-08 Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール Active JP7782035B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025153429A JP2025178324A (ja) 2021-11-09 2025-09-16 Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163277343P 2021-11-09 2021-11-09
US63/277,343 2021-11-09
US202263354403P 2022-06-22 2022-06-22
US63/354,403 2022-06-22
PCT/US2022/049220 WO2023086319A1 (en) 2021-11-09 2022-11-08 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025153429A Division JP2025178324A (ja) 2021-11-09 2025-09-16 Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール

Publications (3)

Publication Number Publication Date
JP2024540292A JP2024540292A (ja) 2024-10-31
JP2024540292A5 JP2024540292A5 (https=) 2025-07-07
JP7782035B2 true JP7782035B2 (ja) 2025-12-08

Family

ID=84541585

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024526576A Active JP7782035B2 (ja) 2021-11-09 2022-11-08 Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール
JP2025153429A Pending JP2025178324A (ja) 2021-11-09 2025-09-16 Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025153429A Pending JP2025178324A (ja) 2021-11-09 2025-09-16 Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール

Country Status (8)

Country Link
US (2) US11970494B2 (https=)
EP (1) EP4430042B1 (https=)
JP (2) JP7782035B2 (https=)
AU (1) AU2022388555A1 (https=)
CA (1) CA3234638A1 (https=)
DK (1) DK4430042T3 (https=)
TW (1) TW202334139A (https=)
WO (1) WO2023086319A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11691963B2 (en) 2020-05-06 2023-07-04 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2023086319A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2
WO2024229295A1 (en) * 2023-05-03 2024-11-07 Ajax Therapeutics, Inc. Forms and compositions of a jak2 inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
JP2007509058A (ja) 2003-10-16 2007-04-12 カイロン コーポレイション Ｒａｆキナーゼインヒビターとしての置換ベンゾアゾールおよびその使用
WO2020097396A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2021226261A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Family Cites Families (267)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2729545B2 (ja) 1991-06-05 1998-03-18 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料用の処理液及びそれを用いた処理方法
DK152291D0 (da) 1991-08-28 1991-08-28 Danisco Fremgangsmaade og kemiske forbindelser
US5994629A (en) 1991-08-28 1999-11-30 Novartis Ag Positive selection
BR9305569A (pt) 1992-07-03 1995-12-26 Kumiai Chemical Industry Co Derivados heterocíclicos condensados e herbicidas
US5852046A (en) 1993-08-03 1998-12-22 Hoechst Aktiengesellschaft Benzo-fused heterocyclic compounds having a 5-membered ring processes for their preparation their use as medicaments their use as diagnostic agents and medicaments containing them
EP0639573A1 (de) 1993-08-03 1995-02-22 Hoechst Aktiengesellschaft Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
FR2719843B1 (fr) 1994-05-10 1996-06-07 Synthelabo Dérivés de 5,6-dihydro-4h-imidazo [2',1':2,3] imidazo-[4,5,1-ij] quinoléine et de 4,5-dihydroimidazo [1,2-a] pyrrolo-[1,2,3-cd] benzimidazole, leur préparation et leur application en thérapeutique.
DE4441676A1 (de) 1994-11-23 1996-05-30 Basf Ag Iminooxymethylenanilide, Verfahren zu ihrer Herstellung und ihre Verwendung
DE19507913C2 (de) 1995-03-07 1998-04-16 Agfa Gevaert Ag Farbfotografisches Silberhalogenidmaterial
EA199800308A1 (ru) 1995-09-18 1998-10-29 Басф Акциенгезельшафт Фенилуксусные кислоты, способ их получения и содержащие их средства
CN1056370C (zh) 1995-10-17 2000-09-13 化学工业部沈阳化工研究院 具有除草活性的４－芳氧（硫或氨）基嘧啶衍生物及其制备
US6444816B1 (en) 1997-10-27 2002-09-03 Dr. Reddy's Research Foundation Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
WO1999026932A1 (en) 1997-11-26 1999-06-03 Axys Pharmaceuticals, Inc. By amidino group substituted heterocyclic derivatives and their use as anticoagulants
JPH11283746A (ja) 1998-03-27 1999-10-15 Fuji Photo Film Co Ltd ビスベンゾアゾール化合物を用いたエレクトロルミネッセンス素子およびビスベンゾアゾール化合物の製造方法
CA2332318A1 (en) 1998-05-22 1999-12-02 Juan I. Luengo G-csf mimetics
AU752272B2 (en) 1998-05-22 2002-09-12 Smithkline Beecham Corporation G-CSF mimetics
US6329383B1 (en) 1999-01-25 2001-12-11 Pharmacia Ab 2-amino-5-pyrimidine acetic acid compounds
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
ES2231179T3 (es) 1999-04-12 2005-05-16 Aventis Pharma Limited Compuestos de heteroarilo biciclicos sustituidos como antagonistas de la integrina.
JP4000711B2 (ja) 1999-04-13 2007-10-31 東レ株式会社 発光素子
CA2372836C (en) 1999-05-05 2009-01-20 Aventis Pharma Limited Substituted pyrrolidines as cell adhesion inhibitors
EP1065208A1 (en) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
EP1065207A1 (en) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
DE60031886T2 (de) 1999-12-17 2007-09-06 Ariad Pharmaceuticals, Inc., Cambridge Purinderivate
AU2583901A (en) 1999-12-17 2001-06-25 Ariad Pharmaceuticals, Inc. Proton pump inhibitors
JP2003531111A (ja) 1999-12-17 2003-10-21 アライアッド・ファーマシューティカルズ・インコーポレーテッド プロトンポンプインヒビター
IL150594A0 (en) 2000-01-07 2003-02-12 Ustav Ex Botan Adademie Ved Ce Purine derivatives, process for their preparation and use
GB0004686D0 (en) 2000-02-28 2000-04-19 Aventis Pharma Ltd Chemical compounds
AU2001238690A1 (en) 2000-03-14 2001-09-24 Sepracor, Inc. 3-substituted piperidines comprising urea functionality, and methods of use thereof
EP1272483A2 (en) 2000-03-24 2003-01-08 Millenium Pharmaceuticals, Inc. OXINDOLE INHIBITORS OF FACTOR Xa
WO2001072712A1 (en) 2000-03-24 2001-10-04 Cor Therapeutics, Inc. ISOQUINOLONE INHIBITORS OF FACTOR Xa
JP2004517080A (ja) 2000-11-29 2004-06-10 グラクソ グループ リミテッド Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
US6693125B2 (en) 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US20030009034A1 (en) 2001-03-22 2003-01-09 Neil Wishart Transition metal mediated process
US20030109714A1 (en) 2001-03-22 2003-06-12 Neil Wishart Transition metal mediated process
US20040171630A1 (en) 2001-06-19 2004-09-02 Yuntae Kim Tyrosine kinase inhibitors
WO2003037860A2 (en) 2001-10-30 2003-05-08 Conforma Therapeutics Corporation Purine analogs having hsp90-inhibiting activity
EP1460067A4 (en) 2001-11-26 2005-12-07 Takeda Pharmaceutical BICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
US20040006117A1 (en) 2002-02-15 2004-01-08 Schering Aktiengesellschaft Microglia inhibitors for interrupting interleukin 12 and IFN-gamma-mediated immune reactions
US8299108B2 (en) 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
WO2003082272A1 (en) 2002-03-29 2003-10-09 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
EP1511736A4 (en) 2002-06-07 2006-06-07 Cortical Pty Ltd THERAPEUTIC MOLECULES AND METHOD 1
WO2004002990A2 (en) 2002-06-27 2004-01-08 F. Hoffmann-La Roche Ag Synthesis of purine derivatives
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
AU2003251904A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
JP2004067629A (ja) 2002-08-09 2004-03-04 Yamanouchi Pharmaceut Co Ltd ミトコンドリア機能活性化剤及び新規なベンゾイミダゾール誘導体
AU2002951247A0 (en) 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
US7820682B2 (en) 2002-10-03 2010-10-26 Ono Pharmaceutical Co., Ltd. LPA receptor antagonist
JP4768265B2 (ja) 2002-10-15 2011-09-07 シンタ ファーマシューティカルズ コーポレーション 新規化合物
CN100376573C (zh) 2002-12-04 2008-03-26 卫材R&D管理有限公司 稠合的1,3-二氢-咪唑环化合物
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
WO2004100525A2 (en) 2003-05-05 2004-11-18 Thomson Licensing S.A. System and method for blocking television signal having multiple different content ratings
WO2005000404A2 (en) 2003-05-29 2005-01-06 Synta Pharmaceuticals, Corp. Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
WO2005028447A1 (en) 2003-09-22 2005-03-31 S*Bio Pte Ltd Benzimidazole derivates: preparation and pharmaceutical applications
WO2005035526A1 (en) 2003-10-09 2005-04-21 Argenta Discovery Ltd. Bicyclic compounds and their therapeutic use
US7256196B1 (en) 2003-12-09 2007-08-14 The Procter & Gamble Company Purine cytokine inhibitors
US20050137234A1 (en) 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
CA2547785A1 (en) 2003-12-19 2005-07-21 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
BRPI0508259A (pt) 2004-03-04 2007-07-31 Kissei Pharmaceutical derivado heterocìclico fundido, composição medicinal contendo o mesmo, e uso medicinal do mesmo
JP4528013B2 (ja) 2004-04-01 2010-08-18 三井化学株式会社 アントラセン化合物、および該アントラセン化合物を含有する有機電界発光素子
TWI380816B (zh) 2004-04-13 2013-01-01 Synta Pharmaceuticals Corp 抑制介白素-１２（ｉｌ-１２）生成之二鹽抑制劑
WO2005112932A2 (en) 2004-05-07 2005-12-01 Exelixis, Inc. Raf modulators and methods of use
US7687638B2 (en) 2004-06-04 2010-03-30 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7371264B2 (en) 2004-08-26 2008-05-13 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
US7371737B2 (en) 2004-09-09 2008-05-13 Solvay Pharmaceuticals, B.V. 2-substituted-6-trifluoromethyl purine derivatives with adenosine-A3 antagonistic activity
AR050630A1 (es) 2004-09-09 2006-11-08 Solvay Pharm Bv DERIVADOS DE 6- TRIFLUOROMETIL PURINA 2- SUSTITUIDA CON ACTIVIDAD ANTAGONISTA DE ADENOSINA-A3. PROCESOS DE OBTENCIoN Y COMPOSICIONES FARMACÉUTICAS.
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
MX2007004783A (es) 2004-10-21 2007-05-11 Pfizer Inhibidores de la proteasa del virus de la hepatitis c, y composiciones y tratamientos que los usan.
EP1828144A2 (en) 2004-11-12 2007-09-05 OSI Pharmaceuticals, Inc. Integrin antagonists useful as anticancer agents
US7429608B2 (en) 2005-01-20 2008-09-30 Amgen Inc. Benzo[d]imidazol analogs as vanilloid receptor ligands and their use in treatments
WO2006127550A1 (en) 2005-05-23 2006-11-30 Merck & Co., Inc. Proline bis-amide orexin receptor antagonists
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
US20070032493A1 (en) 2005-05-26 2007-02-08 Synta Pharmaceuticals Corp. Method for treating B cell regulated autoimmune disorders
WO2006130469A1 (en) 2005-05-27 2006-12-07 Oregon Health & Science University Stimulation of neurite outgrowth by small molecules
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
JPWO2007007463A1 (ja) 2005-07-11 2009-01-29 出光興産株式会社 電子吸引性置換基を有する含窒素複素環誘導体及びそれを用いた有機エレクトロルミネッセンス素子
US20090278115A1 (en) 2005-07-11 2009-11-12 Idemitsu Kosan Co., Ltd. Nitrogen-containing heterocyclic derivative and organic electroluminescence element using the same
JP2007039406A (ja) 2005-08-05 2007-02-15 Idemitsu Kosan Co Ltd 含窒素複素環誘導体及びそれを用いた有機エレクトロルミネッセンス素子
US7825154B2 (en) 2005-08-12 2010-11-02 The United States Of America As Represented By The Secretary Of The Army Small molecule inhibitors of botulinum neurotoxins
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
WO2007064932A2 (en) 2005-12-02 2007-06-07 Bayer Healthcare Llc. Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
EA034598B1 (ru) 2005-12-23 2020-02-25 Ариад Фармасьютикалз, Инк. Применение бициклических гетероарильных соединений для лечения рака
JP2009525955A (ja) 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2007091950A1 (en) 2006-02-07 2007-08-16 Astrazeneca Ab Benzimidazoles and imidazopyridines useful in the treatment of diseases or disorders associated with cannabinoid receptor 2 (cb2) such as pain
CN101379060B (zh) 2006-02-10 2012-05-23 转化技术制药公司 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
EP2010530A2 (en) 2006-03-23 2009-01-07 Novartis AG Methods for the preparation of imidazole-containing compounds
CA2649288C (en) 2006-04-19 2015-11-24 Novartis Ag 6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
EP2700638A1 (en) 2006-05-31 2014-02-26 The Regents Of the University of California Purine analogs
US20080008682A1 (en) 2006-07-07 2008-01-10 Chong Lee S Modulators of toll-like receptor 7
WO2008016666A2 (en) 2006-08-02 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
EP2061786A2 (en) 2006-09-07 2009-05-27 Biogen Idec MA Inc. Indazole derivatives as modulators of interleukin-1 receptor-associated kinase
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
US7825261B2 (en) 2006-12-05 2010-11-02 National Taiwan University Indazole compounds
JP2010514695A (ja) 2006-12-21 2010-05-06 プレキシコン，インコーポレーテッド キナーゼ調節のための化合物および方法およびそのための適応症
US20080161254A1 (en) 2007-01-03 2008-07-03 Virobay, Inc. Hcv inhibitors
WO2008124145A1 (en) 2007-04-05 2008-10-16 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Steroid compounds, compositions, and methods of treatment
WO2008136948A1 (en) 2007-05-07 2008-11-13 Amgen Inc. Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as p38 modulators, process for their preparation, and their pharmaceutical use
AU2008254425A1 (en) 2007-05-21 2008-11-27 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
CL2008001626A1 (es) 2007-06-05 2009-06-05 Takeda Pharmaceuticals Co Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
CA2691444C (en) 2007-06-29 2016-06-14 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
JP5306344B2 (ja) 2007-07-12 2013-10-02 ケモセントリックス， インコーポレイテッド 炎症の治療のためのｃｃｒ２モジュレーターとしての縮合ヘテロアリールピリジルおよびフェニルベンゼンスルホンアミド
WO2009011775A1 (en) 2007-07-13 2009-01-22 Merck & Co., Inc. Amidoethyl alkylamino orexin receptor antagonists
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
CA2695989A1 (en) 2007-08-10 2009-02-19 Glaxosmithkline Llc Certain nitrogen containing bicyclic chemical entities for treating viral infections
JP5350247B2 (ja) 2007-08-29 2013-11-27 武田薬品工業株式会社 複素環化合物およびその用途
WO2009034386A1 (en) 2007-09-13 2009-03-19 Astrazeneca Ab Derivatives of adenine and 8-aza-adenine and uses thereof-796
BRPI0818003A2 (pt) 2007-10-18 2019-09-24 Novartis Ag inibidores de csf-1r, composições e métodos de uso
JP2009149589A (ja) 2007-12-24 2009-07-09 Dnp Fine Chemicals Co Ltd 非対称モノアザメチンシアニンの製造方法
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
CA2721060A1 (en) 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010002492A1 (en) 2008-04-29 2010-01-07 University Of Chicago Methods of use of adenine derivatives for the treatment of diabetes and other disorders
US20110039895A1 (en) 2008-04-30 2011-02-17 Glaxo Smith Kline LLC., a corporation Prolyl hydroxylase inhibitors
US20100197688A1 (en) 2008-05-29 2010-08-05 Nantermet Philippe G Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
WO2009155565A1 (en) 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine jak inhibitor compounds and methods
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
US20100093747A1 (en) 2008-10-10 2010-04-15 Erica Brook Goodhew Method of inducing negative chemotaxis
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
WO2010084300A2 (en) 2009-01-22 2010-07-29 Iti Scotland Limited Stem cell culture methods
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
WO2010124097A2 (en) 2009-04-22 2010-10-28 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
EP2438066A2 (en) 2009-06-05 2012-04-11 Cephalon, Inc. PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES
WO2010143733A1 (en) 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
US9556426B2 (en) 2009-09-16 2017-01-31 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
EP2542076B1 (en) 2010-03-04 2021-01-13 Merck Sharp & Dohme Corp. Inhibitors of catechol o-methyl transferase and their use in the treatment of psychotic disorders
BR112012022801B8 (pt) 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
SI2556071T1 (sl) 2010-04-06 2016-12-30 University Health Network Kinazni inhibitorji in njihova uporaba pri zdravljenju raka
CN102219725B (zh) 2010-04-16 2013-10-09 中国科学院上海药物研究所 苯并杂环类化合物及其制备方法和用途
WO2011133661A2 (en) 2010-04-21 2011-10-27 Research Development Foundation Methods and compositions related to dopaminergic neuronal cells
WO2011142381A1 (ja) 2010-05-11 2011-11-17 Fujita Takashi ベンゾ若しくはピリドイミダゾール誘導体
NZ604306A (en) 2010-05-17 2015-02-27 Incozen Therapeutics Pvt Ltd Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
MX2012015143A (es) 2010-06-30 2013-07-03 Amgen Inc Compuestos heterociclicos que contienen nitrogeno como inhibidores de pi3k delta.
WO2012016133A2 (en) 2010-07-29 2012-02-02 President And Fellows Of Harvard College Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
JP6075621B2 (ja) 2010-08-10 2017-02-08 塩野義製薬株式会社 新規複素環誘導体およびそれらを含有する医薬組成物
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
WO2012033149A1 (ja) 2010-09-10 2012-03-15 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有するヘテロ環縮合イミダゾール誘導体
RU2632900C2 (ru) 2010-11-19 2017-10-11 Лиганд Фармасьютикалс Инкорпорейтед Гетероциклические амины и их применение
EP2646455A4 (en) 2010-12-03 2014-04-02 Epizyme Inc Modulators of histone methyltransferase, and methods of use thereof
US9145438B2 (en) 2010-12-03 2015-09-29 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
US8710082B2 (en) 2011-02-18 2014-04-29 Board Of Trustees Of Michigan State University Benzimidazole inhibition of biofilm formation
CA2829558A1 (en) 2011-03-09 2012-09-13 Celgene Avilomics Research, Inc. Pi3 kinase inhibitors and uses thereof
US20150197497A1 (en) 2011-06-24 2015-07-16 Dana-Farber Cancer Institute, Inc. Selective inhibitors of histone deacetylase isoform 6 and methods thereof
BR112014001018A2 (pt) 2011-07-15 2017-01-10 Shionogi & Co derivado de azabenzimidazol tendo atividade de ativação de ampk
EP2741611A4 (en) 2011-08-08 2015-03-04 California Inst Of Techn SMALL MOLECULAR COMPOUNDS FOR COMBATING PATHOGENIC NEMATODES IN PLANTS AND INSECTS
BR112014003008A2 (pt) 2011-08-08 2017-02-21 Boyce Thompson Intitute For Plant Res "compostos e métodos de modificação de comportamento de um nemátodo”
CA2841801A1 (en) 2011-08-17 2013-02-21 F.Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
US20130096136A1 (en) 2011-09-30 2013-04-18 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
US20130090327A1 (en) 2011-09-30 2013-04-11 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
US10292390B2 (en) 2011-11-04 2019-05-21 Wisconsin Alumni Research Foundation Inhibition and dispersion of bacterial biofilms with 2-aminobenzimidazole derivatives
WO2013106792A1 (en) 2012-01-13 2013-07-18 Acea Biosciences Inc. Heterocyclic compounds and uses as anticancer agents.
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
WO2013118855A1 (ja) 2012-02-09 2013-08-15 塩野義製薬株式会社 複素環および炭素環誘導体
US9284299B2 (en) 2012-02-10 2016-03-15 University Of Utah Research Foundation Substituted 1H-indazol-1-ol analogs as inhibitors of beta catenin/Tcf protein-protein interactions
CN107082779A (zh) 2012-03-30 2017-08-22 理森制药股份公司 作为c‑met 蛋白激酶调节剂的新化合物
EP2847201B1 (en) 2012-05-07 2017-08-16 The University of Queensland 6-oxopurine phosphoribosyltransferase inhibitors
AU2013204604B2 (en) 2012-05-30 2016-05-19 Biodiem Limited Method of treating Scedosporium spp. infection
BR112014030940B1 (pt) 2012-06-11 2022-09-06 UCB Biopharma SRL Benzimidazóis que modulam tnf-alfa e composição farmacêutica compreendendo os mesmos
US9040498B2 (en) 2012-07-06 2015-05-26 Research Foundation Of The City University Of New York 1,2,3-Triazolyl purine derivatives
AR091786A1 (es) 2012-07-17 2015-02-25 Boehringer Ingelheim Int Inhibidores de la produccion de leucotrienos
US20150216168A1 (en) 2012-09-05 2015-08-06 Bayer Cropscience Ag Use of substituted 2-amidobenzimidazoles, 2-amidobenzoxazoles and 2-amidobenzothiazoles or salts thereof as active substances against abiotic plant stress
WO2014069426A1 (ja) 2012-10-31 2014-05-08 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有するベンズイミダゾールおよびアザベンズイミダゾール誘導体
GB201220157D0 (en) 2012-11-08 2012-12-26 Selvita Sa Substitute tricyclic benzimidazoles as kinase inhibitors
WO2014144455A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. 1 -phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
JP6372891B2 (ja) 2013-04-24 2018-08-15 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有する５−オキシベンズイミダゾールおよび５−オキシアザベンズイミダゾール誘導体
PT2994465T (pt) 2013-05-10 2018-10-25 Karus Therapeutics Ltd Novos inibidores de histona desacetilase
US9783504B2 (en) 2013-07-09 2017-10-10 Dana-Farber Cancer Institute, Inc. Kinase inhibitors for the treatment of disease
JP2016169161A (ja) 2013-07-19 2016-09-23 大日本住友製薬株式会社 新規イミダゾピリジン化合物
EP3670496A3 (en) 2013-10-17 2020-09-30 Shionogi&Co., Ltd. Acc2 inhibitors
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
BR112016012243A2 (pt) 2013-12-09 2017-08-08 Ucb Biopharma Sprl Derivados de imidazopiridina como moduladores de atividade de tnf
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321748D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US10403825B2 (en) 2014-02-27 2019-09-03 Universal Display Corporation Organic electroluminescent materials and devices
US9190620B2 (en) 2014-03-01 2015-11-17 Universal Display Corporation Organic electroluminescent materials and devices
WO2015188369A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
WO2015193506A1 (en) 2014-06-20 2015-12-23 Institut Pasteur Korea Anti-infective compounds
TWI719942B (zh) 2014-07-21 2021-03-01 瑞士商諾華公司 使用ｃｄ３３嵌合抗原受體治療癌症
CN116655603A (zh) 2014-07-21 2023-08-29 默克专利有限公司 用于电子器件的材料
WO2016060963A1 (en) 2014-10-14 2016-04-21 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
JP2016079168A (ja) 2014-10-17 2016-05-16 塩野義製薬株式会社 ９員縮合環誘導体
CA2965781A1 (en) 2014-10-28 2016-05-06 Shionogi & Co., Ltd. Heterocyclic derivative having ampk activating effect
EP3230279A1 (en) 2014-12-10 2017-10-18 Massachusetts Institute of Technology Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
JP2016132649A (ja) 2015-01-21 2016-07-25 大日本住友製薬株式会社 新規イミダゾピリジン誘導体およびその医薬用途
KR101987994B1 (ko) 2015-01-28 2019-06-11 제이엔 테라퓨틱스 치환된 이미다조[1,2-a]피리딘-2-일아민 화합물, 및 약학 조성물 및 이의 사용 방법
US10696972B2 (en) 2015-02-19 2020-06-30 St. Jude Children's Research Hospital, Inc. Method for improving learning
WO2016161952A1 (zh) 2015-04-07 2016-10-13 广东众生药业股份有限公司 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物
WO2016196991A1 (en) 2015-06-04 2016-12-08 Children's Hospital Medical Center Therapeutic targeting of myeloproliferative neoplasms by dusp1 inhibition
US10875833B2 (en) 2015-06-12 2020-12-29 Transitions Optical, Inc. Alignment compounds
GB2545499A (en) 2015-12-18 2017-06-21 Cambridge Display Tech Ltd Dopant, charge transfer salt and organic electronic device
WO2017053537A1 (en) 2015-09-23 2017-03-30 Capella Therapeutics, Inc. Benzimidazoles for use in the treatment of cancer and inflammatory diseases
US10973913B2 (en) 2016-02-16 2021-04-13 Washington University JAK inhibitors and uses thereof
GB201603311D0 (en) 2016-02-25 2016-04-13 Jakobsson Per Johan New uses and methods
US10526345B2 (en) 2016-04-08 2020-01-07 Mankind Pharma Ltd. Compounds as GPR119 agonists
EP3450435A4 (en) 2016-04-26 2019-09-18 Shionogi & Co., Ltd SUBSTITUTED AZABENZIMIDAZOLE DERIVATIVE IN POSITION 5 HAVING AN AMPK ACTIVATION ACTION
CN109476661A (zh) 2016-05-20 2019-03-15 盐野义制药株式会社 具有ampk活化作用的5-取代苯并咪唑及5-取代氮杂苯并咪唑衍生物
WO2018035061A1 (en) 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
WO2018064498A1 (en) 2016-09-30 2018-04-05 Pairnomix, Llc Methods of treating epilepsy and related neurological conditions
CA3037587A1 (en) 2016-09-30 2018-04-05 Epizyme, Inc. Substituted fused bi- or tri- heterocyclic compounds as ehmt2 inhibitors
JP6899993B2 (ja) 2016-10-04 2021-07-07 国立医薬品食品衛生研究所長 複素環化合物
WO2018086593A1 (zh) 2016-11-11 2018-05-17 礼沃（上海）医药科技有限公司 含氮杂环化合物、制备方法、中间体、药物组合物和应用
US20200039998A1 (en) 2016-12-19 2020-02-06 Epizyme, Inc. Amine-substituted heterocyclic compounds as ehmt2 inhibitors and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3656382A1 (en) 2017-01-30 2020-05-27 Université de Liège Perk and ire-1a inhibitors against neurodevelopmental disorders
US20200268753A1 (en) 2017-01-30 2020-08-27 Université de Liège Perk and ire-1a inhibitors against neurodevelopmental disorders
WO2018151326A1 (ja) 2017-02-20 2018-08-23 国立大学法人京都大学 スプライシング異常に起因する遺伝性疾病のための医薬組成物及び治療方法
FR3064268A1 (fr) 2017-03-23 2018-09-28 Universite De Montpellier Acyclonucleosides phosphonates, leurs prodrogues, et leur utilisation en tant que medicaments.
US20200113901A1 (en) 2017-03-31 2020-04-16 Epizyme, Inc. Methods of using ehmt2 inhibitors
WO2018191146A1 (en) 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof
CN108689942B (zh) 2017-04-11 2023-06-09 广东东阳光药业有限公司 含氮双环化合物及其制备方法和用途
WO2018195123A1 (en) 2017-04-18 2018-10-25 Tempest Therapeutics, Inc. Bicyclic compounds and their use in the treatment of cancer
CN110621316B (zh) 2017-04-21 2024-01-26 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
WO2018200608A1 (en) 2017-04-26 2018-11-01 The Board Of Trustees Of The University Of Illinois Nrf and hif activators/hdac inhibitors and therapeutic methods using the same
US11957931B2 (en) 2017-04-26 2024-04-16 Yale University Compositions and methods for treating vitiligo
CA3062829A1 (en) 2017-05-03 2018-11-08 Universite Grenoble Alpes Method for synthesizing diversely substituted purines
WO2018204765A1 (en) 2017-05-05 2018-11-08 Pairnomix, Llc Methods of treating epilepsy and kcnq2 related conditions
CN107383014B (zh) 2017-06-21 2019-04-30 南方医科大学 一种1H-吡唑并[3,4-d]嘧啶类化合物及其制备方法和应用
EA201992780A1 (ru) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
CN110582491B (zh) 2017-06-30 2023-09-29 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
WO2019018119A1 (en) 2017-07-18 2019-01-24 Pairnomix, Llc METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI
EP3661496A4 (en) 2017-08-01 2021-04-21 Opal Biosciences Limited TREATMENT OF STAPHYLOCOCCAL AND ENTEROCOCCAL INFECTIONS WITH SUBSTITUTED NITROSTYRENE COMPOUNDS
WO2019038683A1 (en) 2017-08-24 2019-02-28 Institute For Stem Cell Biology And Regenerative Medicine COMPOUNDS TARGETING BRCA1 BRCT TANDEM DOMAINS, COMPOSITIONS AND RELATED METHODS
RU2020113612A (ru) 2017-10-11 2021-11-12 Хемоцентрикс, Инк. Лечение фокально-сегментарного гломерулосклероза антагонистами ccr2
CA3079260A1 (en) 2017-10-17 2019-04-25 Epizyme, Inc. Amine-substituted heterocyclic compounds as ehmt2 inhibitors and derivatives thereof
JP2021500326A (ja) 2017-10-18 2021-01-07 エピザイム，インコーポレイティド 血液障害の予防又は処置にｅｈｍｔ２阻害剤を使用する方法
AU2018353139A1 (en) 2017-10-18 2020-06-04 Epizyme, Inc. Methods of using EHMT2 inhibitors in immunotherapies
JP2021035910A (ja) 2017-11-01 2021-03-04 大日本住友製薬株式会社 置換プリン化合物
KR102706420B1 (ko) 2017-11-30 2024-09-13 솔브레인 주식회사 화합물 및 이를 포함하는 유기 발광 소자
CN110092798A (zh) 2018-01-29 2019-08-06 上海新契博生物科技有限公司 一种作为fgfr抑制剂的杂环化合物及其合成方法和应用
EP3790540A4 (en) 2018-05-11 2022-05-18 The University of Arizona METHODS OF TREATMENT OR LIMITATION OF THE DEVELOPMENT OF CARDIOVASCULAR DISEASE RELATED TO NEUROLOGICAL DISEASES
EP3820500A4 (en) 2018-07-13 2022-04-13 Teqla Therapeutics, Inc. USE OF BCL6 INHIBITORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
MX2021004191A (es) 2018-10-15 2021-05-27 Nurix Therapeutics Inc Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
AR117189A1 (es) 2018-11-02 2021-07-21 Aicuris Gmbh & Co Kg Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb)
EP3877371A4 (en) 2018-11-07 2022-07-27 Dana-Farber Cancer Institute, Inc. IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
CN117186092A (zh) 2018-11-07 2023-12-08 四川科伦博泰生物医药股份有限公司 并环化合物、其制备方法及用途
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2020118045A1 (en) 2018-12-05 2020-06-11 Aldeyra Therapeutics, Inc. Injectable formulations
IL264854A (en) 2019-02-14 2020-08-31 Bahat Anat Spt5 inhibitors and methods of use thereof
MX2021010198A (es) 2019-02-27 2021-09-21 Univ California Indoles n-sustituidos y otros heterociclos para el tratamiento de trastornos cerebrales.
MX2021010319A (es) 2019-03-01 2021-12-10 Revolution Medicines Inc Compuestos biciclicos de heteroarilo y usos de estos.
MX2021010701A (es) 2019-03-05 2022-02-21 F Star Therapeutics Inc Compuestos, composiciones y metodos para el tratamiento de enfermedad.
US20220213064A1 (en) 2019-04-12 2022-07-07 National Health Research Institutes Heterocyclic compounds as kinase inhibitors for therapeutic uses
IL287183B2 (en) 2019-04-12 2025-01-01 Mitobridge Inc Inductors 1 HMOX
WO2020243457A1 (en) 2019-05-29 2020-12-03 Viogen Biosciences, Llc Compounds and therapeutic uses thereof
AU2020357983B2 (en) 2019-10-03 2025-11-13 Dana-Farber Cancer Institute, Inc. Tricyclic kinase inhibitors and uses thereof
US20230024442A1 (en) 2019-11-08 2023-01-26 Nurix Therapeutics, Inc. Bifunctional compounds for grading btk via ubiquitin proteosome pathway
WO2021113557A1 (en) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
US12043632B2 (en) 2020-12-23 2024-07-23 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
WO2023086319A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
JP2007509058A (ja) 2003-10-16 2007-04-12 カイロン コーポレイション Ｒａｆキナーゼインヒビターとしての置換ベンゾアゾールおよびその使用
WO2020097396A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
WO2021226261A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACS Medicinal Chemistry Letters，2014年，Vol.5，pp.989-992
Cancer Cell，2015年，Vol.28，pp.29-41

Also Published As

Publication number Publication date
US20240254125A1 (en) 2024-08-01
JP2025178324A (ja) 2025-12-05
JP2024540292A (ja) 2024-10-31
EP4430042B1 (en) 2026-02-18
AU2022388555A1 (en) 2024-05-02
TW202334139A (zh) 2023-09-01
WO2023086319A1 (en) 2023-05-19
US11970494B2 (en) 2024-04-30
DK4430042T3 (da) 2026-04-13
CA3234638A1 (en) 2023-05-19
EP4430042A1 (en) 2024-09-18
US20230167110A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
JP7782035B2 (ja) Ｊａｋ２阻害剤としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール
JP7793540B2 (ja) Ｊａｋ２阻害薬としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール
JP7763767B2 (ja) ヘテロアリール複素環式化合物およびその使用
HK1223100A1 (zh) 杂环化合物
CN103119045A (zh) 吡咯并嘧啶化合物及其用途
WO2025209278A1 (en) A pyrrolo [2, 3-b] pyridine derivative, and preparation method therefor and use thereof
JP2025528119A (ja) Ｊａｋ２阻害剤としての複素環式アミド及び尿素化合物
CN118201928A (zh) 作为jak2抑制剂的6-杂芳基氧基苯并咪唑和氮杂苯并咪唑
WO2023009712A1 (en) Heteroaryloxy thiazolo azines as jak2 inhibitors
WO2023009709A1 (en) Pyrazolo piperazines as jak2 inhibitors
WO2024148247A2 (en) Azaindazoles as jak2 inhibitors
HK40121672A (zh) 杂芳基杂环化合物及其用途
HK40074266B (zh) 杂芳基杂环化合物及其用途
TW202602445A (zh) 作為ｋｒａｓ調節劑的螺環化合物及其用途
HK40130202A (zh) 杂芳基杂环化合物及其用途
HK40094658B (zh) 杂芳基杂环化合物及其用途
HK40094658A (zh) 杂芳基杂环化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250626

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250716

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250916

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251126

R150 Certificate of patent or registration of utility model

Ref document number: 7782035

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150